Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Inventory (2023 - 2025)

Zhengye Biotechnology Holding has reported Inventory over the past 3 years, most recently at $311311.7 for Q4 2025.

  • Quarterly Inventory fell 79.27% to $311311.7 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $311311.7 through Dec 2025, down 79.27% year-over-year, with the annual reading at $316000.0 for FY2025, 78.62% down from the prior year.
  • Inventory was $311311.7 for Q4 2025 at Zhengye Biotechnology Holding, down from $1.7 million in the prior quarter.
  • Over five years, Inventory peaked at $8.1 million in Q4 2023 and troughed at $311311.7 in Q4 2025.
  • The 3-year median for Inventory is $1.6 million (2024), against an average of $2.9 million.
  • Year-over-year, Inventory crashed 81.45% in 2024 and then tumbled 79.27% in 2025.
  • A 3-year view of Inventory shows it stood at $8.1 million in 2023, then crashed by 81.45% to $1.5 million in 2024, then tumbled by 79.27% to $311311.7 in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Inventory are $311311.7 (Q4 2025), $1.7 million (Q2 2025), and $1.5 million (Q4 2024).